ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

What Are the Peri-Operative and Longterm Outcomes of Utilizing Donation after Circulatory Death Livers with Macrosteatosis? A Multicenter Analysis

K. Croome1, A. Mathur2, S. Mao1, B. Aqel3, P. Senada1, J. Piatt1, J. Heimbach4, A. Moss3, C. Rosen4, C. Taner1

1Mayo Clinic Jacksonville, Jacksonville, FL, 2Mayo Clinic Arizona, Scotsdale, AZ, 3Mayo Clinic Arizona, Scottsdale, AZ, 4Mayo Clinic Rochester, Rochester, MN

Meeting: 2020 American Transplant Congress

Abstract number: 43

Keywords: Donors, marginal, Donors, non-heart-beating, Graft failure

Session Information

Date: Saturday, May 30, 2020

Session Name: Liver: MELD, Allocation and Donor Issues (DCD/ECD) I

Session Time: 3:15pm-4:45pm

 Presentation Time: 3:51pm-4:03pm

Location: Virtual

Related Abstracts
  • Sequential Protocol Biopsies Post-Liver Transplant from Donors with Moderate Macrosteatosis: What Happens to the Fat?
  • Not for the Faint of Heart: The Impact of Post-Reperfusion Syndrome during Liver Transplantation Using Livers with Significant Macrosteatosis

*Purpose: Given the potentially additive risk from using donor livers that are both steatotic and from a donation after circulatory death(DCD) donor, there is a paucity of data on the outcome of DCD liver transplantation(LT) utilizing livers with macrosteatosis.The present study involves three large volume DCD centers that have increasingly utilized steatotic DCD livers over time.

*Methods: All DCD LT performed at Mayo Clinic-Florida(MCF), Mayo Clinic-Arizona(MCA) and Mayo Clinic-Rochester(MCR) from 1999-2019 were included(N=714). Recipients of DCD LT were divided into 3 groups: those with Moderate Macrosteatosis(30-60%), Mild Macrosteatosis(5-30%) and No Steatosis. All liver biopsies were evaluated by an experienced liver pathologist at MCF, MCA or MCR.

*Results: Patients with Moderate Macrosteatosis had a higher rate of post-reperfusion syndrome (PRS)(53.9% vs. 26%;p=0.01), post-reperfusion cardiac arrest(7.7% vs.0.3%;p<0.001), primary non-function(PNF)(7.7%vs.1.0%;p=0.003), early allograft dysfunction(EAD)(70.8%vs.45.6% and 8.3%;p=0.02) and acute kidney injury (AKI)(39.1%vs.19.4%; p=0.02) than patients with No Steatosis. No difference in any of the peri-operative complications was seen between the Mild Macrosteatosis and the No Steatosis groups except for the rate of EAD(56.8%vs.45.6%;p=0.04). No difference in ischemic cholangiopathy(IC), vascular thrombosis/stenosis or graft and patient survival was seen between the three groups.

*Conclusions: DCD donors with mild macrosteatosis <30% can be utilized with no increase in peri-operative complications and similar patient and graft survival compared to DCD donors with no steatosis. When utilizing DCD donors with moderate macrosteatosis (30-60%), higher rates of PRS, PNF, post-reperfusion cardiac arrest, EAD and AKI should be anticipated. If recipients are able to tolerate these peri-operative events, a similar long-term patient and graft survival compared to DCD livers with no steatosis can potentially be achieved. In addition, donor steatosis does not appear to be correlated with the rate of post-LT IC.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Croome K, Mathur A, Mao S, Aqel B, Senada P, Piatt J, Heimbach J, Moss A, Rosen C, Taner C. What Are the Peri-Operative and Longterm Outcomes of Utilizing Donation after Circulatory Death Livers with Macrosteatosis? A Multicenter Analysis [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/what-are-the-peri-operative-and-longterm-outcomes-of-utilizing-donation-after-circulatory-death-livers-with-macrosteatosis-a-multicenter-analysis/. Accessed April 23, 2021.

« Back to 2020 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Deceased Non-A2 Donor ABO-Incompatible Liver Transplantation – Promising Results with Anti-A/B Antibody Reduction Both Pre- and Post-Transplant.
  • Penis Transplantation: First U.S. Experience.
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Penis Transplantation: First U.S. Experience.
  • Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.